[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
D000328:Adult; D000367:Age Factors; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011300:Preoperative Care; D011788:Quality of Life; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D012307:Risk Factors; D012673:Semustine / Q000627:therapeutic use; D012737:Sex Factors; D014750:Vincristine / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D012673:Semustine; D014750:Vincristine; D002955:Leucovorin; D005472:Fluorouracil
Le choix des thérapeutiques du cancer du rectum. Paris, 1er et 2 décembre 1994, Chambre de Commerce et d'industrie. Conférence de consensus.